Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh

Clinical Infectious Diseases

Volumn 42, Issue 3, 2006, Pages 356-362

  Bennish, Michael L ^a,b,c   Khan, Wasif A ^d   Begum, Monira ^d   Bridges, Emily A ^d   Ahmed, Sabeena ^d   Saha, Debasish ^d   Salam, Mohammad A ^d   Acheson, David ^b,g   Ryan, Edward T ^d,e,f  

^a AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ICDDR B Centre for Health and Population Research   (Bangladesh)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; PIVMECILLINAM; SHIGA TOXIN;

ARTICLE; BANGLADESH; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DISEASE DURATION; DRUG EFFICACY; DRUG USE; DYSENTERY; FECES ANALYSIS; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK REDUCTION; SHIGELLA DYSENTERIAE; SHIGELLA DYSENTERIAE TYPE 1; SHIGELLOSIS;

ANTI-BACTERIAL AGENTS; BANGLADESH; CHILD; CHILD, PRESCHOOL; DYSENTERY, BACILLARY; FECES; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; MALE; RISK FACTORS; SHIGA TOXIN; SHIGELLA DYSENTERIAE;

EID: 31044433714     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/499236     Document Type: Article

References (22)

1. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930-6.
2. Greco KM, McDonough MA, Butterton JR. Variation in the Shiga toxin region of 20th-century epidemic and endemic Shigella dysenteriae 1 strains. J Infect Dis 2004; 190:330-4.
3. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000; 181: 664-70.
4. Al-Qarawi S, Fontaine KE, Al-Qahtani MS. An outbreak of hemolytic uremic syndrome associated with antibiotic treatment of hospital inpatients for dysentery. Emerg Infect Dis 1995; 1:138-40.
5. Bin Saeed AA, El Bushra HE, Al-Hamdan NA. Does treatment of bloody diarrhea due to Shigella dysenteriae type I with ampicillin precipitate hemolytic uremic syndrome? Emerg Infect Dis 1995; 1:134-7.
6. Butler T, Islam MR, Azad MA, Jones PK. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987; 110: 894-7.
7. Salam MA, Dhar U, Khan WA, Bennish ML. Randomised comparison of ciprofloxacin suspension and pivmecillinam for childhood shigellosis. Lancet 1998; 352:522-7.
8. Zimbabwe, Bangladesh, South Africa (ZIMHASA) Dyscntary Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002; 21:1136-41.
9. Esteve J, Benhamou E, Raymond L. Descriptive epidemiology: statistical methods in cancer research. Lyons: International Agency for Research on Cancer, 1994.
10. Bennish ML, Salam MA, Haider R, Barza M. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 1990; 162:711-6.
11. Bennish ML, Salam MA, Khan WA, Khan AM. Treatment of shigellosis. III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy: a randomized, blinded trial. Ann Intern Med 1992; 117: 727-34.
12. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. Treatment of shigellosis. V. Comparison of azithromycin and ciprofloxacin: a double-blind, randomized, controlled trial. Ann Intern Med 1997; 126:697-703.
13. Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113:901-7.
14. Salam MA, Bennish ML. Antimicrobial therapy for shigellosis. Rev Infect Dis 1991; 13(Suppl 4):S332-41.
15. Salam MA, Seas C, Khan WA, Bennish ML. Treatment of shigellosis. IV. Cefixime is ineffective in shigellosis in adults. Ann Intern Med 1995; 123:505-8.
16. Ryan ET, Dhar U, Khan WA, et al. Mortality, morbidity, and microbiology of endemic cholera among hospitalized patients in Dhaka, Bangladesh. Am J Trop Med Hyg 2000; 63:12-20.
17. Guerin PJ, Brasher C, Baron K, et al. Shigella dysenteriae serotype 1 in West Africa: intervention strategy for an outbreak in Sierra Leone. Lancet 2003; 362:705-6.
18. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651-66.
19. Beutin L, Strauch E, Fischer I. Isolation of Shigella sonnei lysogenic for a bacteriophage encoding gene for production of Shiga toxin. Lancet 1999; 353:1498.
20. Keusch GT. Shigella and enteroinvasive Escherichia coli. In: Blaser MJ, Smith PD, Ravelin JI, Greenberg HB, Guerrant RL, eds. Infections of the gastrointestinal tract. 2nd ed. Philadelphia: Lippincott Williams and Wilkins, 2002:643-67.
21. Rahaman MM, Jamiul Alam AK, Islam MR, Greenough WB III. Shiga bacillus dysentery associated with marked leukocytosis and erythrocyte fragmentation. Johns Hopkins Med J 1975; 136:65-70.
22. Houdouin V, Doit C, Mariani P, et al. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clin Infect Dis 2004; 38:e96-9.